Multi-modal treatment for metastatic renal cancer: The role of surgery

World Journal of Urology

Volumn 28, Issue 3, 2010, Pages 295-301

  Russo, Paul ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Cytoreductive nephrectomy; Metastasectomy; Metastatic renal cancer; Renal cancer

Indexed keywords

ANTINEOPLASTIC AGENT;

ADJUVANT CHEMOTHERAPY; ADJUVANT THERAPY; ARTICLE; CANCER STAGING; DISEASE FREE SURVIVAL; DRUG DELIVERY SYSTEM; FEMALE; HUMAN; KIDNEY CARCINOMA; KIDNEY TUMOR; LYMPH NODE; LYMPH NODE METASTASIS; MALE; METASTASIS; METHODOLOGY; MORTALITY; MULTIMODALITY CANCER THERAPY; NEPHRECTOMY; PATHOLOGY; PATIENT SELECTION; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; ROLE PLAYING; SURVIVAL; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, RENAL CELL; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; KIDNEY NEOPLASMS; LYMPH NODES; LYMPHATIC METASTASIS; MALE; NEOADJUVANT THERAPY; NEOPLASM STAGING; NEPHRECTOMY; PATIENT SELECTION; PROGNOSIS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK ASSESSMENT; ROLE; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 77952883384     PISSN: 07244983     EISSN: 14338726     Source Type: Journal    
DOI: 10.1007/s00345-010-0530-x     Document Type: Article

References (30)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ (2009) Cancer statistics, 2009. Ca Cancer J Clin 59: 225-249.
2. Motzer RJ, Russo P (2000) Systemic therapy for renal cell carcinoma. J Urol 163: 408-417.
3. Rini B, Campbell SC, Escudier B (2009) Renal cell carcinoma. Lancet 373: 1119-1132.
4. Kroog GS, Motzer RJ (2008) Systemic therapy for metastatic renal cell carcinoma. Urol Clin N Am 35: 687-701.
5. Russo P, O'Brien MF (2008) Surgical intervention in patients with metastatic renal cancer: metastasectomy and cytoreductive nephrectomy. Urol Clin North Am 35: 679-686.
6. Barney JD, Churchill EJ (1939) Adenocarcinoma of the kidney with metastasis to the lung: cured by nephrectomy and lobectomy. J Urol 42: 269-276.
7. Giuliani L, Giberti C, Martorana G et al (1990) Radical extensive surgery for renal cell carcinoma: long-term results and prognostic factors. J Urol 143: 468-473.
8. Pogrebniak HW, Haas G, Linehan WM et al (1992) Renal cell carcinoma: resection of solitary and multiple metastases. Ann Thorac Surg 54: 33-38.
9. Kavolius JP, Mastorakos DP, Pavolvich C, Russo P, Burt ME, Brady MS (1998) Resection of metastatic renal cell carcinoma. J Clin Oncol 16: 2261.
10. Russo P, Snyder M, Vickers A, Kondagunta V, Motzer R (2007) Cytoreductive nephrectomy and nephrectomy/complete metastasectomy for metastatic renal cancer. TSW Urol 2: 42-52.
11. Walther MM, Yang JC, Pass HI, Linehan WM, Rosenberg SA (1997) Cytoreductive surgery before high dose interleukin-2 based therapy in patients with metastatic renal cell carcinoma. J Urol 158: 1675.
12. Kutikov A, Uzzo RG, Caraway A, Reese CT, Egleston BL, Chen DY, Viterbo R, Greenberg RE, Wong YN, Raman JD, Boorjian SA (2009) Use of systemic therapy and factors affecting survival for patients undergoing cytoreductive nephrectomy. BJU Int [Epub ahead of print].
13. Bex A, Haanen J, Vyth-Dreese FA, Hornblas S, de Gast GC (2008) Cytokine therapy response as a selection criterion for cytoreductive nephrectomy in metastatic renal cell-clear carcinoma of intermediate prognosis. Urol Int 80: 367-371.
14. Flanigan RC, Salmon SE, Blumenstein BA, Bearman SI, Roy V, McGrath PC, Caton JR, Munshi N, Crawford ED (2001) Nephrectomy followed by interferon α 2-b compared with interferon alfa-2b alone for metastatic renal cell carcinoma. N Engl J Med 345: 1655-1659.
15. Mickisch GHJ, von Poppel H, de Prijck L, Sylvester R et al (2001) Radical nephrectomy plus interferon-alfa based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomized trial. Lancet 358: 966-970.
16. Flanigan RC, Mickisch G, Sylvester R, Tangen C, von Poppel HV, Crawford ED (2004) Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J Urol 171: 1071-1076.
17. Russo P (2009) Contemporary cytoreductive nephrectomy in patients with mRCC. CML Kidney Cancer 1: 33-41.
18. Bromwich E, Hendry D, Aitchison M (2002) Cytoreductive nephrectomy: is it a realistic option in patients with renal cancer. BJU Int 89: 523-525.
19. Motzer RJ, Mazumdar M, Bacik J et al (1999) Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol 17: 2859-2867.
20. Eggener SE, Yossepowitch O, Pettus JA, Snyder ME, Motzer RJ, Russo P (2006) Renal cell carcinoma recurrence after nephrectomy for localized disease. Predicting survival from time of recurrence. J Clin Oncol 24: 3101-3131.
21. Shuck B, LaRochelle JC, Wu J, Klatte T, Riggs SP, Kabbinavar F, Belledegrun AS, Pantuck AJ (2008) Performance status and cytoreductive nephrectomy: redefining management in patients with poor performance. Cancer 113: 1324-1331.
22. Halbert RJ, Figlin RA, Atkins MB et al (2006) Treatment of patients with metastatic renal cell cancer: a RAND appropriateness panel. Cancer 107: 2375-2383.
23. Thomas AA, Rini BI, Lane BR, Garcia J, Dreicer R, Klein EA, Novick AC, Campbell SC (2009) Response of the primary tumor to neoadjuvant sunitinib in patients with advanced renal cell carcinoma. J Urol 181: 518-523.
24. Margulis V, Matin S, Tannir N, Tamboli P, Swanson DA, Jonasch E, Wood CG (2008) Surgical morbidity associated with administration of targeted molecular therapies before cytoreductive nephrectomy or resection of locally recurrent renal cell carcinoma. J Urol 180: 94-98.
25. Neill MG, Jewett MAS (2008) The once and future role of cytoreductive nephrectomy. Urol Oncol 26: 346-352.
26. Coppin C, Le L, Porzolt F, Wilt T (2008) Targeted therapy for advanced renal cell carcinoma. Cochrane Database Syst Rev Issue 2, Art. No CD 006017.
27. Motzer RJ, Bacik J, Mariani T, Russo P, Mazumdar M, Reuter V (2002) Treatment outcome and survival associated with metastatic renal cell carcinoma of non-clear cell histology. J Clin Oncol 20: 2376-2381.
28. Raberts JC, Kaouk J, Fergany A et al (2004) Laparoscopic v open cytoreductive nephrectomy for metastatic renal cell carcinoma. Urology 64: 930-934.
29. Matin SF, Madsen LT, Wood CG (2006) Laparoscopic cytoreductive nephrectomy: the M. D. Anderson Cancer Center Experience. Urology 68: 528-532.
30. Bhojani N, Jeldres C, Patard JJ et al (2008) Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma. Eur Urol 53: 917-930.